Citing anonymous sources involved in a Phase III trial, STAT News reported Sunday that MorphoSys’ pelabresib may worsen the ...

MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly ...

Novartis AG raised its forecast as sales of blockbuster medicines for heart disease and psoriasis outpaced expectations, ...

Zolgensma, a one-off treatment for infants born with a rare and often fatal genetic disease, came to the market five years ...

Novartis now predicts full-year sales will climb by high-single-digit to low-double-digit percent, up from its earlier ...

Sales of Entresto and Cosentyx grew faster in the first quarter than analysts anticipated, helping drive the quarterly beat and raise.

BERLIN (Reuters) -Morphosys said its takeover by Novartis is still expected to close in the first half of this year, after a news report on a possible drug safety risk knocked the German biotechnology ...

Novartis has been hit with a lawsuit by people with autism and their mothers alleging the drugmaker illegally promoted an ...

And its most promising drug, a groundbreaking Alzheimer’s treatment that it ... signaling that the ramp could be accelerating. Importantly, that boost occurred even though Biogen hasn’t yet expanded ...

Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of double-digit growth for its blockbuster ...